CD138 (syndecan-1) expression in health and disease

Histology and Histopathology

Volumn 29, Issue 2, 2014, Pages 177-189

  Palaiologou, Marina ^a   Delladetsima, Ioanna ^a   Tiniakos, Dina ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Carcinoma; CD138; Metastasis; Prognosis; Syndecan 1

Indexed keywords

SDC1 PROTEIN, HUMAN; SYNDECAN 1;

ARTICLE; CELL PROLIFERATION; GENETICS; HUMAN; METABOLISM; NEOPLASM;

CELL PROLIFERATION; HUMANS; NEOPLASMS; SYNDECAN-1;

EID: 84892743838     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (128)

1. Al-Shibli K., Al-Saad S., Andersen S., Donnem T., Bremnes R.M. and Busund L.T. (2010). The prognostic value of intraepithelial and stromal CD3-, CD117 and CD138-positive cells in non-small cell lung carcinoma. APMIS 118, 371-382.
2. Alexander C.M., Reichsman F., Hinkes M.T., Lincecum J., Becker K.A., Cumberledge S. and Bernfield M. (2000). Syndecan-1 is required for Wnt-1-induced mammary tumourigenesis in mice. Nat. Genet. 25, 329-332.
3. Anttonen A., Kajanti M., Heikkilä P., Jalkanen M. and Joensuu H. (1999). Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br. J. Cancer 79, 558-564.
4. Anttonen A., Heikkilä P., Kajanti M., Jalkanen M. and Joensuu H. (2001). High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 2, 297-305.
5. Anttonen A., Leppä S., Ruotsalainen T., Alfthan H., Mattson K. and Joensuu H. (2003). High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 41, 171-177.
6. Anttonen A., Leppä S., Heikkilä P., Grenman R. and Joensuu H. (2006). Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations. J. Cancer Res. Clin. Oncol. 132, 451-457.
7. Baba F., Swartz K., van Buren R., Eickhoff J., Zhang Y., Wolberg W. and Friedl A. (2006). Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor negative, highly proliferative breast carcinoma subtype. Breast Cancer Treat. 98, 91-98.
8. Barbareschi M., Maisonneuve P., Aldovini D., Cangi M.G., Pecciarini L., Angelo Mauri F., Veronese S., Caffo O., Lucenti A., Palma P.D., Galligioni E. and Doglioni C. (2003). High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98:, 475-483.
9. Bayer-Garner I.B. and Reed J.A. (2004). Immunolabeling pattern of syndecan-1 expression may distinguish pagetoid Bowen's disease, extramammary Paget's disease, and pagetoid malignant melanoma in situ. J. Cutan. Pathol. 31, 169-173.
10. Bayer-Garner I.B., Dilday B., Sanderson R.D. and Smoller B.R. (2000). Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma. Am. J. Dermatopathol. 22, 119-122.
11. Beauvais D.M., Ell B.J., McWhorter A.R. and Rapraeger A.C. (2009). Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J. Exp. Med. 206, 691-705.
12. Bologna-Molina R., González-González R., Mosqueda-Taylor A., Molina-Frechero N., Damián-Matsumura P. and Dominguez-Malagón H. (2010). Expression of syndecan-1 in papillary carcinoma of the thyroid with extracapsular invasion. Arch. Med. Res. 41, 33-37.
13. Brimo F., Vollmer R.T., Friszt M., Corcos J. and Bismar T.A. (2010). Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression. BJU Int. 106:418-423.
14. Brockstedt U., Dobra K., Nurminen M. and Hjerpe A. (2002) Immunoreactivity to cell surface syndecans in cytoplasm and nucleus: tubulin-dependent rearrangements. Exp Cell Res. 274, 235-245.
15. Brule S., Charnaux N., Sutton A., Ledoux D., Chaigneau T., Saffar L. and Gattegno L. (2006). The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 6, 488-501.
16. Chen D., Adenekan B., Chen L., Vaughan E.D., Gerald W., Feng Z. and Knudsen B.S. (2004). Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 63, 402-407.
17. Chen C.L. and Ou D.L. (2006) Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis. Hum. Pathol. 37, 1279-1288.
18. Conejo J.R., Kleeff J., Koliopanos A., Matsuda K., Zhu Z.W., Goecke H., Bicheng N., Zimmermann A., Korc M., Friess H. and Büchler M.W. (2000). Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int. J. Cancer 88, 12-20.
19. Contreras H.R., Ledezma R.A., Vergara J., Cifuentes F., Barra C., Cabello P., Gallegos I., Morales B., Huidobro C. and Castellón E.A. (2010). The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. Urol. Oncol. 28, 534-540.
20. Choi D.S., Kim J.H., Ryu H.S., Kim H.C., Han J.H., Lee J.S. and Min C.K. (2007). Syndecan-1, a key regulator of cell viability in endometrial cancer. Int. J. Cancer 121, 741-750.
21. Davies E.J., Blackhall F.H., Shanks J.H., David G., McGown A.T., Swindell R., Slade R.J., Martin-Hirsch P., Gallagher J.T. and Jayson G.C. (2004). Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin. Cancer Res. 10, 5178-5186.
22. Day R.M., Hao X., Ilyas M., Daszak P., Talbot I.C. and Forbes A. (1999). Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch. 434, 121-125.
23. Dedes P.G., Gialeli Ch., Tsonis A.I., Kanakis I., Theocharis A.D., Kletsas D., Tzanakakis G.N. and Karamanos N.K. (2012). Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochim Biophys Acta. 1820, 1926-1939.
24. Derksen P.W., Keehnen R.M., Evers L.M., van Oers M.H., Spaargaren M. and Pals S.T. (2002). Surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99, 1405-1410.
25. Dews I.C. and Mackenzie K.R. (2007). Transmembrane domains of the syndecan family of growth factor coreceptors display a hierarchy of homotypic and heterotypic interactions. Proc. Natl. Acad. Sci. USA 104, 20782-20787.
26. Ding K., Lopez-Burks M., Sánchez-Duran J.A., Korc M. and Lander A.D. (2005). Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J. Cell Biol. 171, 729-738.
27. Endo K., Takino T., Miyamori H., Kinsen H., Yoshizaki T., Furukawa M. and Sato H. (2003). Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J. Biol. Chem. 278, 40764-40770.
28. Fears C.Y. and Woods A. (2006). The role of syndecans in disease and wound healing. Matrix Biol. 25, 443-456.
29. Fujiya M., Watari J., Ashida T., Honda M., Tanabe H., Fujiki T., Saitoh Y. and Kohgo Y. (2001). Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn. J. Cancer Res. 92, 1074-1081.
30. Gattei V., Godeas C., Degan M., Rossi F.M., Aldinucci D. and Pinto A. (1995). Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. Br. J. Haematol. 91, 55-59.
31. Gökden N., Greene G.F., Bayer-Garner I.B., Spencer H.J., Sanderson R.D. and Gökden M. (2006). Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade. Appl. Immunohistochem. Mol. Morphol. 14, 173-177.
32. Götte M., Kersting C., Ruggiero M., Tio J., Tulusan A.H., Kiesel L. and Wülfing P. (2006). Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res. 26, 621-627.
33. Götte M., Kersting C., Radke I., Kiesel L. and Wülfing P. (2008). An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res. 9, R8.
34. Hanahan D. and Weinberg R. (2011) Hallmarks of cancer: the next generation Cell. 144, 646-674.
35. Harada K., Masuda S., Hirano M. and Nakanuma Y. (2003). Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum. Pathol. 34, 857-863.
36. Hasengaowa., Kodama J., Kusumoto T., Shinyo Y., Seki N. and Hiramatsu Y. (2005). Prognostic significance of syndecan-1 expression in human endometrial cancer. Ann. Oncol. 16, 1109-1115.
37. Hashimoto Y., Skacel M. and Adams J.C. (2008). Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumours. BMC Cancer 8, 185-189.
38. Huang M.F., Zhu Y.Q., Chen Z.F., Xiao J., Huang X., Xiong Y.Y. and Yang G.F. (2010). Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancer. World J. Gastroenterol. 11, 2975-2980.
39. Ikeda H., Hideshima T., Fulciniti M., Lutz R.J., Yasui H., Okawa Y., Kiziltepe T., Vallet S., Pozzi S., Santo L., Perrone G., Tai Y.T., Cirstea D., Raje N.S., Uherek C., Dälken B., Aigner S., Osterroth F., Munshi N., Richardson P. and Anderson K.C. (2009). The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res.15, 4028-4037.
40. Inki P., Joensuu H., Grénman R., Klemi P. and Jalkanen M. (1994). Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br. J. Cancer 70, 319-323.
41. Ishikawa T. and Kramer R.H. (2010). Sdc1 negatively modulates carcinoma cell motility and invasion. Exp. Cell. Res. 316, 951-965.
42. Ito Y., Yoshida H., Nakano K., Takamura Y., Miya A., Kobayashi K., Yokozawa T., Matsuzuka F., Matsuura N., Kuma K. and Miyauchi A. (2003). Syndecan-1 expression in thyroid carcinoma, stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 43, 157-164.
43. Jilani I., Wei C., Bekele B.N., Zhang Z.J., Keating M., Wierda W., Ferrajoli A., Estrov Z., Kantarjian H., O'Brien S.M., Giles F.J. and Albitar M. (2009). Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int. J. Lab. Hematol. 31, 97-105.
44. Joensuu H., Anttonen A., Eriksson M., Mäkitaro R., Alfthan H., Kinnula V. and Leppä S. (2002). Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res. 62, 5210-7.
45. Juuti A., Nordling S., Lundin J., Louhimo J. and Haglund C. (2005). Syndecan-1 expression--a novel prognostic marker in pancreatic cancer. Oncology 68, 97-106.
46. Khotskaya Y.B., Dai Y., Ritchie J.P., MacLeod V., Yang Y., Zinn K. and Sanderson R.D. (2009). Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumours in vivo. J. Biol. Chem. 284, 26085-26095.
47. Kim H., Choi D.S., Chang S.J., Han J.H., Min C.K., Chang K.H. and Ryu H.S. (2010). The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinoma. J. Gynecol. Oncol. 21, 50-55.
48. Kim Y.I., Lee A., Lee H. and Kim S.Y. (2011). Prognostic significance of syndecan-1 expression in cervical cancers. J. Gynecol. Oncol. 22, 161-167.
49. Kiviniemi J., Kallajoki M., Kujala I., Matikainen M.T., Alanen K., Jalkanen M. and Salmivirta M. (2004). Altered expression of syndecan-1 in prostate cancer. APMIS 112, 89-97.
50. Kurokawa H., Zhang M., Matsumoto S., Yamashita Y., Tanaka T., Takamori K., Igawa K., Yoshida M., Fukuyama H., Takahashi T. and Sakoda S. (2006). Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma. J. Oral. Pathol. Med. 35, 301-306.
51. Kusumoto T., Kodama J., Seki N., Nakamura K., Hongo A. and Hiramatsu Y. (2010). Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol. Rep. 23, 917-925.
52. Kylänpää L., Hagström J., Lepistö A., Linjama T., Kärkkäinen P., Kiviluoto T. and Haglund C. (2009). Syndecan-1 and Tenascin expression in cystic tumours of the pancreas. J. Pancreas 10, 378-382.
53. Lambaerts K, Wilcox-Adelman S.A. and Zimmermann P. (2009). The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr. Opin. Cell Biol. 21, 662-669.
54. Lamorte S., Ferrero S., Aschero S., Monitillo L., Bussolati B., Omedè P., Ladetto M. and Camussi G. (2012). Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Leukemia 26, 1081-1090.
55. Leivonen M., Lundin J., Nordling S., von Boguslawski K. and Haglund C. (2004). Prognostic value of syndecan-1 expression in breast cancer. Oncology 67, 11-18.
56. Lendorf M.E., Manon-Jensen T., Kronqvist P., Multhaupt H.A. and Couchman J.R. (2011). Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J. Histochem. Cytochem. 59, 615-629.
57. Li H.G., Xie D.R., Shen X.M., Li H.H., Zeng H. and Zeng Y.J. (2005). Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J. Gastroenterol. 11, 1445-1451.
58. Liu B.Y., McDermott S.P., Khwaja S.S. and Alexander C.M. (2004). The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. PNAS 10, 4158-4163.
59. Lofgren L., Sahlin L., Jiang S., Von Schoultz B., Fernstad R., Skoog L. and Von Schoultz E. (2007). Expression of Syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women. Anticancer Res. 27, 3045-3050.
60. Loussouarn D., Campion L., Sagan C., Frenel J.S., Dravet F., Classe J.M., Pioud-Martigny R., Berton-Rigaud D., Bourbouloux E., Mosnier J.F., Bataille F.R. and Campone M. (2008). Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br. J. Cancer 98, 1993-1998.
61. Lovell R., Dunn J.A., Begum G., Barth N.J., Plant T., Moss P.A., Drayson M.T. and Pratt G. (2005). Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. Br. J. Haematol. 130, 542-548.
62. Lu Z.L., Zhang W.M., Xiao G., Zhang M., Xie D., Xu F.P., Liang X.J., Bi S.J. and Wen J.M. (2006). Study of expression of CD138 and heparanase in hepatocellular carcinoma by tissue microarray. Zhonghua Bing Li Xue Za Zhi. 35, 82-86 (in chinesse).
63. Lundin M., Nordling S., Lundin J., Isola J., Wiksten J.P. and Haglund C. (2005). Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 68, 306-313.
64. Maeda T, Desouky J, and Friedl A. (2006). Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 25, 1408-1412.
65. Manon-Jensen T., Itoh Y. and Couchman J.R. (2010). Proteoglycans in health and disease, the multiple roles of syndecan shedding. FEBS J. 277, 3876-3889.
66. Margadant C., Monsuur H.N., Norman J.C. and Sonnenberg A. (2011). Mechanisms of integrin activation and trafficking. Curr. Opin. Cell Biol. 23, 607-614.
67. Martinez A., Spencer M.L., Brethanor U., Cerez P., Marchesani F.J. and Rojas I.G. (2009). Deduction of syndecan-1 expression during lip carcinogenesis. J. Oral Pathol. Med. 38, 580-583.
68. Máthé M., Suba Z., Németh Z., Tátrai P., Füle T., Borgulya G., Barabás J. and Kovalszky I. (2006). Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas. Oral Oncol. 42, 493-500.
69. Matsumoto A., Ono M., Fujimoto Y., Gallo R.L., Bernfield M. and Kohgo Y. (1997). Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int. J. Cancer 74, 482-491.
70. McQuade K.J., Beauvais D.M., Burbach B.J. and Rapraeger A.C. (2006). Syndecan-1 regulates alphavbeta5 integrin activity in B82L fibroblasts. J. Cell Sci. 119, 2445-2456.
71. Mennerich D., Vogel A., Klaman I., Dahl E., Lichtner R.B., Rosenthal A., Pohlenz H.D., Thierauch K.H. and Sommer A. (2004). Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur. J. Cancer 40, 1373-1382.
72. Mikami S., Ohashi K., Usui Y., Nemoto T., Katsube K., Yanagishita M., Nakajima M., Nakamura K. and Koike M. (2001). Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn. J. Cancer Res. 92, 1062-1073.
73. Minowa K., Amano H., Nakano S., Ando S., Watanabe T., Nakiri Y., Amano E., Tokano Y., Morimoto S. and Takasaki Y. (2011). Elevated serum level of circulating syndecan-1 (CD138) in active systemic lupus erythematosus. Autoimmunity 44, 357-362.
74. Metwaly H.A., Al-Gayyar M.M., Eletreby S., Ebrahim M.A. and El-Shishtawy M.M. (2012). Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma. Sci. Pharm. 80, 179-188.
75. Mitselou A., Ioachim E., Peschos D., Charalabopoulos K., Michael M., Agnantis N.J. and Vougiouklakis T. (2007). E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp. Oncol. 29, 54-60.
76. Molica S., Vitelli G., Mirabelli R., Digiesu G., Giannarelli D., Cuneo A., Ribatti D. and Vacca A. (2006). Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia, correlation with the extent of angiogenesis and disease-progression risk in early disease. Leuk. Lymphoma 47, 1034-1040.
77. Nault J.C., Guyot E., Laguillier C., Chevret S., Ganne-Carrie N., N'Kontchou G., Beaugrand M., Seror O., Trinchet J.C., Coelho J., Lassalle P., Charnaux N., Delehedde M., Sutton A. and Nahon P. (2013). Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol. Biomarkers Prev. 22, 1343-1352.
78. Nikolova V., Koo C.Y., Ibrahim S.A., Wang Z., Spillmann D., Dreier R., Kelsch R., Fischgräbe J., Smollich M., Rossi L.H., Sibrowski W.,Wülfing P., Kiesel L., Yip G.W. and Götte M. (2009). Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 30, 397-407.
79. Numa F., Hirabayashi K., Kawasaki K., Sakaguchi Y., Sugino N., Suehiro Y., Suminami Y., Hirakawa H., Umayahara K., Nawata S., Ogata H. and Kato H. (2002). Syndecan-1 expression in cancer of the uterine cervix, association with lymph node metastasis. Int. J. Oncol. 20, 39-43.
80. O'Connell F.P., Pinkus J.L. and Pinkus G.S. (2004). CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am. J. Clin. Pathol. 121, 254-263.
81. Oh J.H., Kim J.H., Ahn H.J., Yoon J.H., Yoo S.C., Choi D.S, Lee I.S, Ryu H.S. and Min C.K. (2009). Syndecan-1 enhances the endometrial cancer invasion by modulating matrix metalloproteinase-9 expression through nuclear factor kappaB. Gynecol. Oncol. 114, 509-515.
82. Orecchia P., Conte R., Balza E., Petretto A., Mauri P., Mingari M.C. and Carnemolla B. (2013) A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma. Eur J Cancer 49, 2022-2033.
83. Patonai A., Erdélyi-Belle B., Korompay A., Somorácz A., Törzsök P., Kovalszky I., Barbai T., Rásó E., Lotz G., Schaff Z. and Kiss A. (2012). Molecular characteristics of fibrolamellar hepatocellular carcinoma. Pathol. Oncol. Res.19, 63-70.
84. Pietras K. and Ostman A. (2010). Hallmarks of cancer, interactions with the tumour stroma. Exp. Cell Res. 316, 1324-1331.
85. Pruessmeyer J., Martin C., Hess F.M., Schwarz N., Schmidt S., Kogel T., Hoettecke N., Schmidt B., Sechi A., Uhlig S. and Ludwig A. (2010). A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells. J. Biol. Chem. 285, 555-564.
86. Pulkkinen J.O., Penttinen M., Jalkanen M., Klemi P. and Grénman R. (1997). Syndecan-1, a new prognostic marker in laryngeal cancer. Acta Otolaryngol. 117, 312-315.
87. Purushothaman A., Uyama T., Kobayashi F., Yamada S., Sugahara K., Rapraeger A.C. and Sanderson R.D. (2010). Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115, 2449-2457.
88. Ramalingam P., Adeagbo B., Bollag R., Lee J. and Reid-Nicholson M. (2008). Metastatic hepatocellular carcinoma with CD138 positivity, an unusual mimic of multiple myeloma? Diagn. Cytopathol. 36, 742-748.
89. Ramani V.C., Purushothaman A., Stewart M.D., Thompson C.A., Vlodavsky I., Au J.L. and Sanderson R.D. (2011). Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J. Biol. Chem. 286, 6490-6499.
90. Ramani V.C., Purushothaman A., Stewart M.D., Thompson C.A., Vlodavsky I., Au J.L. and Sanderson R.D. (2013). The heparanase/syndecan-1 axis in cancer, mechanisms and therapies. FEBS J. 280, 2294-2306.
91. Rapraeger A.C. (2013). Synstatin, a selective inhibitor of the syndecan-1-coupled IGF1R-αvß3 integrin complex in tumourigenesis and angiogenesis. FEBS J. 280, 2207-2215.
92. Rintala M., Inki P., Klemi P., Jalkanen M. and Grénman S. (1999). Association of syndecan-1 with tumour grade and histology in primary invasive cervical carcinoma. Gynecol. Oncol. 75, 372-378.
93. Ritchie J.P., Ramani V.C., Ren Y., Naggi A., Torri G., Casu B., Penco S., Pisano C., Carminati P., Tortoreto M., Zunino F., Vlodavsky I., Sanderson R.D. and Yang Y. (2011). SST0001, a chemically modified heparan, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin. Cancer Res. 17, 1382-1393.
94. Ro Y., Muramatsu T., Shima K., Yajima Y., Shibahara T., Noma H. and Shimono M. (2006). Correlation between reduction of syndecan-1 expression and clinico-pathological parameters in squamous cell carcinoma of tongue. Int. J. Oral Maxillofac. Surg. 35, 252-257.
95. Roh Y.H., Kim Y.H., Choi H.J., Lee K.E. and Roh M.S. (2008). Syndecan-1 expression in gallbladder cancer and its prognostic significance. Eur. Surg. Res. 41, 245-250.
96. Roskams T., De Vos R., David G., Van Damme B. and Desmet V. (1998). Heparan sulphate proteoglycan expression in human primary liver tumours. J. Pathol. 18, 290-297.
97. Salani R., Neuberger I., Kurman R.J., Bristow R.E., Chang H.W., Wang T.L. and Shih Ie M. (2007). Expression of extracellular matrix proteins in ovarian serous tumours. Int. J. Gynecol. Pathol. 26, 141-146.
98. Sanderson R.D. and Yang Y. (2008). Syndecan-1, a dynamic regulator of the myeloma microenvironment. Clin. Exp. Metastasis 25, 149-159.
99. Saqi A., Yun S.S., Yu G.H., Alexis D., Taub R.N., Powell C.A. and Borczuk A.C. (2005). Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas. Diagn. Cytopathol. 33, 65-70.
100. Seidel C., Sundan A., Hjorth M., Turesson I., Dahl I.M., Abildgaard N., Waage A. and Borset M. (2000). Serum syndecan-1, a new independent prognostic marker in multiple myeloma Blood 95, 388-392.
101. Shah L., Walter K.L., Borczuk A.C., Kawut S.M., Sonett J.R., Gorenstein L.A., Ginsburg M.E., Steinglass K.M. and Powell C.A. (2004). Expression of Syndecan-1 and Expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 101, 1632-1638.
102. Schmedt A., Götte M., Heinig J., Kiesel L., Klockenbusch W. and Steinhard J. (2012). Evaluation of placental syndecan-1 expression in early pregnancy as a predictive fetal factor for pregnancy outcome. Prenat. Diagn. 32, 131-137.
103. Shariat S.F., Svatek R.S., Kabbani W., Walz J., Lotan Y., Karakiewicz P.I. and Roehrborn C.G. (2008). Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int. 101, 232-237.
104. Shimada K., Nakamura M., De Velasco M.A., Tanaka M., Ouji Y., Miyake M., Fujimoto K., Hirao K. and Konishi N. (2010). Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Cancer Sci.101, 155-160.
105. Shinyo Y., Kodama J., Hasengaowa, Kusumoto T. and Hiramatsu Y. (2005). Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer. Gynecol. Oncol. 96, 776-783.
106. Stepp M.A., Pal-Ghosh S., Tadvalkar G., Rajjoub L., Jurjus R.A., Gerdes M., Ryscavage A., Cataisson C., Shukla A. and Yuspa S.H. (2010). Loss of syndecan-1 is associated with malignant conversion in skin carcinogenesis. Mol. Carcinog. 49, 363-373.
107. Su G., Blaine S.A., Qiao D. and Friedl A. (2007). Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J. Biol. Chem. 282, 14906-14915.
108. Suhovskih V., Mostovich A., Kunin S., Boboev M., Nepomnyashchikh I., Aidagulova V. and Grigorieva V. (2013) Proteoglycan expression in normal human prostate tissue and prostate cancer. ISRN Oncol., 680136.
109. Sun H., Hu Y., Gu Z., Owens R.T., Chen Y.Q. and Edwards I.J. (2011). Omega-3 fatty acids induce apoptosis in human breast cancer cells and mouse mammary tissue through syndecan-1 inhibition of the MEK-Erk pathway. Carcinogenesis 32, 1518-1524.
110. Szumilo J., Burdan F., Zinkiewicz K., Dudka J., Klepacz R., Dabrowski A. and Korobowicz E. (2009). Expression of syndecan-1 and cathepsins D and K in advanced esophageal squamous cell carcinoma. Folia Histochem. Cytobiol. 47, 571-578.
111. Teng Y.H., Aquino R.S. and Park P.W. (2012). Molecular functions of syndecan-1 in disease. Matrix Biol. 31, 3-16.
112. Thanakit V., Ruangvejvorachai P. and Sampatanukul P. (2008). Expression of E-cadherin and syndecan-1 in axillary lymph node metastases of breast cancer with and without extracapsular extension. J. Med. Assoc. Thai. 91, 1087-1092.
113. Theocharis A.D., Skandalis S.S., Tzanakakis G.N. and Karamanos N.K. (2010). Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 277, 3904-3923.
114. Tiniakos D., Palaiologou M., Tsioli P., Felekouras E., Antoniou E. and Delladetsima I. (2009). CD138: a new immunohistochemical marker for hepatocellular carcinoma (HCC)? Virchows Archiv. 45 (supl1l):S113
115. Tiniakos D., Palaiologou M., Karanikolas M., Fatoutou E., Felekouras E., Antoniou E. and Delladetsima J. (2011). Prognostic significance of CD138 immunoexpression in human hepatocellular carcinoma. Virchows Archiv. 459 (suppl 1), S157-158.
116. Tokes A.M., Szasz A.M., Farkas A,. Toth A.I., Dank M., Harsanyi L., Molnar B.A., Molnar I.A., Laszlo Z., Rusz Z. and Kulka J. (2009). Stromal matrix protein expression following preoperative systemic therapy in breast cancer. Clin. Cancer Res. 15, 731-739.
117. Toyoshima E., Ohsaki Y., Nishigaki Y., Fujimoto Y., Kohgo Y. and Kikuchi K. (2001). Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor. Lung Cancer 31, 193-202.
118. Vassilakopoulos T.P., Kyrtsonis M.C., Papadogiannis A., Nadali G., Angelopoulou M.K., Tzenou T., Dimopoulou M.N., Siakantaris M.P., Kontopidou F.N., Kalpadakis C., Kokoris S.I., Dimitriadou E.M., Tsaftaridis P., Pizzolo G. and Pangalis G.A. (2005). Serum levels of soluble syndecan-1 in Hodgkin's lymphoma. Anticancer Res. 25, 4743-4746.
119. Vuoriluoto K., Jokinen J., Kallio K., Salmivirta M., Heino J. and Ivaska J. (2008). Syndecan-1 supports integrin alpha2beta1-mediated adhesion to collagen. Exp. Cell Res. 314, 3369-3381.
120. Vuoriluoto K., Högnäs G., Meller P., Lehti K. and Ivaska J. (2011). Syndecan-1 and -4 differentially regulate oncogenic K-ras dependent cell invasion into collagen through ·2'1 integrin and MT1-MMP. Matrix Biol. 30, 207-217.
121. Wang J.B., Zhang Y.J., Guan J., Zhou L., Sheng Y., Zhang Y. and Si Y.F. (2012). Enhanced syndecan-1 expression on neutrophils in patients with type 2 diabetes mellitus. Acta Diabetol. 49, 41-46.
122. Watari J., Saitoh Y., Fujiya M., Shibata N., Tanabe H., Inaba Y., Okamoto K., Maemoto A., Ohta T., Yasuda A., Ayabe T., Ashida T., Yokota K., Obara T. and Kohgo Y. (2004). Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype. J. Gastroenterol. 39, 104-112.
123. Wiksten J.P., Lundin J., Nordling S., Lundin M., Kokkola A., von Boguslawski K. and Haglund C. (2001). Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int. J. Cancer 95, 1-6.
124. Wiksten J.P., Lundin J., Nordling S., Kokkola A. and Haglund C. (2008). Comparison of the prognostic value of a panel of tissue tumour markers and established clinicopathological factors in patients with gastric cancer. Anticancer Res. 28, 2279-2287.
125. Wu Y.H., Yang C.Y., Chien W.L., Lin K.I. and Lai M.Z. (2012). Removal of syndecan-1 promotes TRAIL-induced apoptosis in myeloma cells. J. Immunol. 188, 2914-2921.
126. Yang N., Mosher R., Seo S., Beebe D. and Friedl A. (2011). Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility. Am. J. Pathol. 178, 325-335.
127. Zellweger T., Ninck C., Mirlacher M., Annefeld M., Glass A.G., Gasser T.C., Mihatsch M.J., Gelmann E.P. and Bubendorf L. (2003). Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 55, 20-29.
128. Zhang S., Qing Q., Wang Q., Xu J., Zhi F., Park P.W., Zhang Y. and Chen Y. (2013). Syndecan-1 and heparanase: potential markers for activity evaluation and differential diagnosis of Crohn's disease. Inflamm. Bowel Dis. 19, 1025-1033.